Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 20 Nov 2018 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 20 Nov 2018 |
| CHMP Issues Positive Opinion on Split Dosing Regimen for DARZALEX® (daratumumab) | 19 Nov 2018 |
| Genmab Announces Financial Results for the First Nine Months of 2018 | 14 Nov 2018 |
| Genmab to Present at the Jefferies 2018 London Healthcare Conference | 8 Nov 2018 |
| Genmab Announces Data to be Presented at 2018 ASH Annual Meeting | 1 Nov 2018 |